News Sentiment

BDTX sentiment intelligence

Black Diamond Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.91 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-5.0% over one week, +9.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -5.0% Price reacting lower
Trend fit Trend inactive 9.1% over four weeks
Fair value -40.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 43
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 12
TradingView 7
www.marketscreener.com 3
TradingKey 3
GlobeNewswire 3
simplywall.st 3
Quartr 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 21
Regulatory and legal 3
Deals and strategy 2
Balance sheet 1
Capital return 1
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Quartr Direct company coverage

Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary

This article summarizes Black Diamond Therapeutics' 24th Annual Needham Virtual Healthcare Conference, held on December 27, 2025. Key highlights include the development of oral oncology therapies, particularly BDTX-1535 for non-small cell lung cancer (NSCLC) and glioblastoma, wit

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 06:41
Source
Quartr
Stock Titan Direct company coverage

T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment

T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 4,028,202 shares of Black Diamond Therapeutics I (BDTX) common stock, which represents a 7.0% stake as of June 30, 2026. The filing specifies that T. Rowe Price holds

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 15:39
Source
Stock Titan
Intellectia AI Direct company coverage

BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison

This article analyzes Black Diamond Therapeutics Inc.'s (BDTX) financial performance, focusing on its profitability and market position. It highlights the company's undefined gross, operating, and net margins, alongside a Return on Equity (ROE) of -35.16%. The analysis also inclu

Tone
Negative 32/100
Event
Regulatory and legal
Published
04 Jul 2026 04:39
Source
Intellectia AI
Stock Titan Direct company coverage

BDTX SEC Filings - Black Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Black Diamond Therapeutics (BDTX) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms (Form 4). Recent filings highlight director stock compensation in lie

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity

Black Diamond Therapeutics director Raman Prakash received a grant of 40,000 stock options with an exercise price of $1.71 per share, expiring on June 25, 2036. The options will vest fully on the earlier of June 26, 2027, or the company's next annual meeting, provided Prakash rem

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 09:09
Source
Stock Titan
Stock Titan Direct company coverage

Black Diamond (BDTX) director awarded 40,000 stock options at $1.71

Black Diamond Therapeutics director Ali Behbahani was granted 40,000 stock options at an exercise price of $1.71 per share, set to expire on June 25, 2036. These compensation awards will vest on the earlier of June 26, 2027, or the company's next annual meeting, provided Behbahan

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

Black Diamond Therapeutics (BDTX) 2026 meeting backs directors, auditor and annual say-on-pay

Black Diamond Therapeutics (BDTX) held its 2026 annual shareholder meeting where stockholders elected Shannon Campbell and Kapil Dhingra as Class III directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending Decembe

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 21:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com

This article reports on a Form 4 filing for Black Diamond Therapeutics Inc. on June 29. It includes the stock symbol BDTX and its current performance (+2.34%). The content primarily shows a stock market overview with various financial data.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 21:09
Source
Investing.com Canada
Stock Titan Direct company coverage

Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71

Samarth Kulkarni, a director at Black Diamond Therapeutics (BDTX), was granted stock options for 40,000 shares of common stock with an exercise price of $1.71 per share. These options are set to vest on the earlier of June 26, 2027, or the company's next annual meeting, contingen

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Black Diamond Therapeutics (BDTX) awards 40,000-share option grant

Black Diamond Therapeutics director Shannon Campbell was granted stock options for 40,000 shares of common stock with an exercise price of $1.71 per share, expiring on June 25, 2036. The options will vest on the earlier of June 26, 2027, or the company’s next annual meeting, prov

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:09
Source
Stock Titan
www.marketscreener.com Direct company coverage

Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 2000 Index

Black Diamond Therapeutics, Inc. (NasdaqGS:BDTX) has been added to the Russell 2000 Index, a significant development for the clinical-stage oncology company. This inclusion follows several recent updates, including positive Phase 2 results for their drug Silevertinib and addition

Tone
Positive 73/100
Event
Earnings
Published
29 Jun 2026 18:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark

Black Diamond Therapeutics, Inc. (NasdaqGS:BDTX) has been added to the Russell 2000 Value Benchmark, as reported on June 29, 2026. This inclusion is part of a series of recent index additions and removals for the company, including being added to the Russell 2000 Index and Russel

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 11:23
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 3000E Index

Black Diamond Therapeutics, Inc. (NasdaqGS: BDTX) has been added to the Russell 3000E Index. The company, a clinical-stage oncology firm, focuses on developing MasterKey therapies for various oncogenic mutations in cancer patients, including its BDTX-1535 drug for NSCLC and gliob

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 06:40
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBITDA forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX

The article focuses on the enterprise value to EBITDA forward for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). It indicates that the company's market is currently closed with no trades. The content primarily lists navigational elements and financial data sources provided by v

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX

The article focuses on the "Price to book forward" metric for Black Diamond Therapeutics, Inc. (BDTX), listed on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data page from TradingView, displaying no actual data but providing context for where suc

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX

This article provides financial information for Black Diamond Therapeutics, Inc. (BDTX) via TradingView. It specifically focuses on the company's price to sales forward metric. The content is part of a larger financial data platform.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:41
Source
TradingView
Quartr Direct company coverage

Black Diamond Therapeutics (BDTX) AGM 2026 Summary

This article provides a summary of Black Diamond Therapeutics (BDTX) 2026 Annual General Meeting (AGM). The virtual meeting addressed formal business, corporate governance, and voting procedures, confirming a quorum with nearly 78% shareholder representation. The summary highligh

Tone
Positive 74/100
Event
Market update
Published
26 Jun 2026 17:10
Source
Quartr
TradingView Direct company coverage

Price to sales forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX

This article displays the "Price to sales forward" metric for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). The content appears to be a stub or a section from a larger financial data platform, showing the stock ticker and market information without detailed financial figures o

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX

This article focuses on the enterprise value to EBIT forward ratio for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The content highlights the specific financial

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 02:42
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX

This article focuses on the price-to-earnings forward metric for Black Diamond Therapeutics, Inc. (BDTX), listed under the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data page from TradingView, providing an overview of the company's financial inform

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 00:42
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Black Diamond Therapeutics Inc For: 22 June By Investing.com

This article announces the filing of Form 4 for Black Diamond Therapeutics Inc. on June 22nd, as reported by Investing.com. It is a brief, one-sentence news piece from an investing news platform. The content primarily focuses on the regulatory filing for the specified company on

Tone
Neutral 50/100
Event
Regulatory and legal
Published
23 Jun 2026 06:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Ali Behbahani of Black Diamond (NASDAQ: BDTX) receives 8,961-share award

Ali Behbahani, a director at Black Diamond Therapeutics (NASDAQ: BDTX), was granted 8,961 shares of common stock valued at $1.66 per share. This award was part of the company's non-employee director compensation policy, allowing him to elect stock in lieu of cash for his annual b

Tone
Neutral 50/100
Event
Balance sheet
Published
22 Jun 2026 20:40
Source
Stock Titan
TradingKey Direct company coverage

Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Black Diamond Therapeutics Inc (BDTX) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The article also presents current stock perf

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 18:39
Source
TradingKey